The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
申请公布号
WO9626278(A1)
申请公布日期
1996.08.29
申请号
WO1995US02366
申请日期
1995.02.24
申请人
GENENTECH, INC.;LAZARUS, ROBERT, A.;SHAK, STEVEN;ULMER, JANA, S.